Basilea Reports Positive MRSA Drug Results
Posted on: Thursday, 11 January 2007, 09:01 CST
Basilea Pharmaceutica has said a second phase III study of ceftobiprole in complicated skin infections has met its primary endpoint and has shown anti-MRSA activity.
The primary endpoint of the trial was statistical non-inferiority versus combination therapy. Ceftobiprole demonstrated high cure rates in patients with skin infections including diabetic patients with foot infections.
In this study 91% of patients were cured with ceftobiprole compared to 90% of patients treated with combination therapy. The clinical response in patients with diabetic foot infections was 86% for ceftobiprole and 82% for comparator combination therapy, respectively. These results show that ceftobiprole monotherapy is superior to standard combination therapy.
Ceftobiprole is an anti-MRSA, broad-spectrum cephalosporin developed in collaboration with Cilag GmbH International, a Johnson & Johnson company. A first regulatory submission for Ceftobiprole is planned this year.
Complicated skin and skin structure infections are among the most common infections in the hospital setting. In recent years resistant strains such as MRSA have become increasingly common and have been associated with increased morbidity and mortality.
Source: Datamonitor
Related Articles
- New Combination Therapy Looks Promising Against Ulcer Bacteria
- U.S. Food and Drug Administration (FDA) Approves PREZISTA(R) Once-Daily As Part of Combination Therapy for Treatment-Naive Adults With HIV-1
- U.S. Food & Drug Administration Approved the Use of REYATAZ(R) (Atazanavir Sulfate) Boosted With Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients
- New Data Released at Major Diabetes Meeting on Initial Combination Therapy With JANUVIA(TM) (Sitagliptin), Merck's Diabetes Medicine, and Metformin Through Two Years of Treatment
- Study Showed Significant and Sustained Efficacy Of COPAXONE(R) Alone Following Short-Term Combination Therapy With IV Steroids in Multiple Sclerosis Patients
- Schering-Plough Announces Global Agreement With Novartis to Develop Once-Daily Combination Therapy for Asthma and COPD
- Diagnostic Utility of Bone Marrow Sampling in HIV-Infected Patients Since the Advent of Highly Active Antiretroviral Therapy
- European Union's CHMP Adopts Positive Opinion For Shorter Course of PEGINTRON(R) and REBETOL(R) Combination Therapy For Certain Hepatitis C Patients With Genotype 1 and Low Viral Load
- Data on PEG-INTRON(R) and REBETOL(R) Combination Therapy in Diverse Patient Populations to Be Presented at 2005 Digestive Disease Week (DDW) Meeting
- Treatment of Hepatitis C in HIV/Hepatitis C Co-Infected Patients: What is the Evidence?
 |
 |
User Comments (0)
RSS Feeds